secondary hyperparathyroidism
Endocrinology · 2005–2019
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cinacalcet Treatment of sustained secondary hyperparathyroidism in patients with chronic kidney disease receiving dialysis that has not responded to conventional therapy. | Jul 2019 | Recommended with restriction | none received |
| cinacalcet Management of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, not responding to conventional therapy. | Mar 2014 | Not recommended | no section in document |
| cinacalcet Treatment of secondary hyperparathyroidism in dialysis patients with chronic kidney disease, and hypercalcemia in parathyroid carcinoma patients. | Nov 2013 | Recommended | no section in document |
| paricalcitol Treatment of secondary hyperparathyroidism in patients with chronic kidney disease where treatment with calcitriol is not appropriate. | Mar 2011 | Not recommended | no section in document |
| paricalcitol Treatment of patients with end-stage renal disease (Stage 5) receiving dialysis who have secondary hyperparathyroidism. | Mar 2009 | Not recommended | no section in document |
| paricalcitol Treatment of secondary hyperparathyroidism in patients with end-stage chronic kidney disease receiving dialysis. | Mar 2008 | Recommended | no section in document |
| paricalcitol Treatment of patients with end stage renal disease receiving dialysis who have secondary hyperparathyroidism (iPTH value > 300 pg/mL). | Jul 2007 | Not recommended | no section in document |
| paricalcitol Treatment of secondary hyperparathyroidism in patients with end-stage renal disease receiving dialysis. | Jul 2007 | Not recommended | no section in document |
| cinacalcet hydrochloride Treatment of secondary hyperparathyroidism in patients with end stage renal disease receiving dialysis who have uncontrolled secondary hyperparathyroidism. | Nov 2007 | Recommended with restriction | no section in document |
| cinacalcet hydrochloride Treatment of secondary hyperparathyroidism in patients with end-stage renal disease receiving dialysis who have uncontrolled secondary hyperparathyroidism. | Nov 2007 | Recommended with restriction | no section in document |
| cinacalcet hydrochloride Treatment of uncontrolled secondary hyperparathyroidism in patients with end-stage renal disease receiving dialysis, demonstrated by an intact PTH value >53… | Jul 2006 | Not recommended | no section in document |
| cinacalcet hydrochloride Treatment of secondary hyperparathyroidism in patients with end stage renal disease receiving dialysis. | Nov 2005 | Not recommended | no section in document |
What the PBS pays
$3M in government benefit over 2024–25, across 65,716 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| cinacalcet | $1.5M |
| cinacalcet hydrochloride | $1.5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| etelcalcetideEtelcalcetide for treating secondary hyperparathyroidism | TA448 | recommended restricted | 2017-06 |
| cinacalcetCinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | not recommended | 2007-01 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.